Revenue
2019
2020
2021
2022
2023
2024
2025
Intercure Ltd. (INCR)
Price$5.16Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | ₪270.2M | ₪238.8M | ₪355.6M | ₪388.7M | ₪219.7M | ₪65.0M | ₪8.9M |
| Gross profit | ₪33.2M | ₪30.2M | ₪105.1M | ₪155.1M | ₪91.1M | ₪32.0M | ₪1.5M |
| Gross margin | 12.28% | 12.66% | 29.56% | 39.90% | 41.48% | 49.17% | 16.57% |
| Research & development | ₪390,000 | ₪414,000 | ₪388,000 | ₪632,000 | ₪1.2M | ₪1.6M | ₪1.7M |
| Operating expenses | ₪26.4M | ₪97.4M | ₪146.7M | ₪104.5M | ₪62.9M | ₪70.4M | ₪4.9M |
| Operating income | ₪6.7M | −₪67.2M | −₪41.6M | ₪50.6M | ₪28.2M | −₪38.4M | −₪3.4M |
| Operating margin | 2.49% | −28.14% | −11.69% | 13.03% | 12.83% | −59.05% | −38.26% |
| EBITDA | −₪7.3M | −₪51.8M | −₪28.4M | ₪62.3M | ₪35.6M | −₪35.1M | −₪2.6M |
| EBITDA margin | −2.70% | −21.70% | −7.99% | 16.04% | 16.20% | −54.04% | −28.98% |
| Net income | −₪35.7M | −₪72.8M | −₪63.5M | ₪43.7M | ₪7.3M | −₪36.0M | −₪5.9M |
| Net profit margin | −13.22% | −30.48% | −17.87% | 11.26% | 3.32% | −55.42% | −66.02% |
| Basic EPSper basic share | — | -₪1.48 | -₪1.36 | ₪0.99 | ₪0.12 | -₪1.42 | -₪0.25 |
| Diluted EPSper diluted share | — | -₪1.48 | -₪1.36 | ₪0.99 | ₪0.11 | -₪1.42 | -₪0.25 |
Insider buys & sells
Community posts
InterCure resolves Nasdaq minimum-bid-price deficiency
InterCure ($INCR) received written confirmation that it has regained compliance with Nasdaq’s minimum-bid-price requirement. Its shares had closed at or above $1 for ten consecutive business days, allowing Nasdaq to close the specific defic ...